Evidence map›Paper›PMID 39006092›Full record

ArticleRadiology case reports2024

Ischemic cholangitis: Lethal complication of Osler-Weber-Rendu disease.

Ouiam Elmqaddem, Hajar Koulali, Abdelkrim Zazour, Meryem Nasiri, Moulay Zahi Ismaili, Ghizlane Kharrasse

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ouiam ElmqaddemDigestive Disease Research Laboratory, Medical School, Mohammed First University, Faculty of Medicine and Pharmacy Oujda, Morocco.
Hajar KoulaliDigestive Disease Research Laboratory, Medical School, Mohammed First University, Faculty of Medicine and Pharmacy Oujda, Morocco.
Abdelkrim ZazourDigestive Disease Research Laboratory, Medical School, Mohammed First University, Faculty of Medicine and Pharmacy Oujda, Morocco.
Meryem NasiriDigestive Disease Research Laboratory, Medical School, Mohammed First University, Faculty of Medicine and Pharmacy Oujda, Morocco.
Moulay Zahi IsmailiDigestive Disease Research Laboratory, Medical School, Mohammed First University, Faculty of Medicine and Pharmacy Oujda, Morocco.
Ghizlane KharrasseDigestive Disease Research Laboratory, Medical School, Mohammed First University, Faculty of Medicine and Pharmacy Oujda, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osler-Weber-Rendu disease (OWRD), also known as hereditary haemorrhagic telangiectasia (HHT), is an autosomal dominant genetic disorder characterised by arteriovenous malformations in several organs. Ischemic cholangitis is a rare life-threatening complication of OWRD, with only a few documented cases in the literature. A liver transplant is the main curative treatment. In this paper, we report a case of a 33-year-old woman with a history of recurrent epistaxis, admitted with abdominal pain and fever, physical examination found multiple cutaneous and mucosal telangiectasias and the biological workup showed cholestasis, abdominal imaging identified arterio-venous shunts and multiple cystic hepatic lesions, one of them seemed to communicate with an intrahepatic biliary duct, finally the diagnosis of ischemic cholangitis due to OWRD was retained and antibiotic treatment has been initiated. We review the various therapeutic options available to improve the management of this fatal complication.

Indexed as

BevacizumabBilomasEpistaxisIschemic cholangitisLiver transplantationRendu Osler Weber disease

Identifiers

PMID39006092
PMCPMC11245895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.